Madrigal Pharmaceuticals Inc (MDGL)
215.99
+5.91
(+2.81%)
USD |
NASDAQ |
May 02, 16:00
215.99
0.00 (0.00%)
After-Hours: 18:20
Madrigal Pharmaceuticals Research and Development Expense (TTM): 272.35M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 272.35M |
| September 30, 2023 | 272.45M |
| June 30, 2023 | 269.77M |
| March 31, 2023 | 259.67M |
| December 31, 2022 | 245.44M |
| September 30, 2022 | 227.59M |
| June 30, 2022 | 214.19M |
| March 31, 2022 | 207.32M |
| December 31, 2021 | 205.16M |
| September 30, 2021 | 205.70M |
| June 30, 2021 | 204.12M |
| March 31, 2021 | 197.18M |
| December 31, 2020 | 184.81M |
| September 30, 2020 | 156.29M |
| June 30, 2020 | 122.44M |
| March 31, 2020 | 93.35M |
| December 31, 2019 | 72.32M |
| September 30, 2019 | 56.28M |
| June 30, 2019 | 43.05M |
| March 31, 2019 | 32.56M |
| December 31, 2018 | 25.39M |
| September 30, 2018 | 23.03M |
| June 30, 2018 | 23.50M |
| March 31, 2018 | 25.21M |
| December 31, 2017 | 24.39M |
| Date | Value |
|---|---|
| September 30, 2017 | 23.40M |
| June 30, 2017 | 24.52M |
| March 31, 2017 | 19.80M |
| December 31, 2016 | 15.93M |
| September 30, 2016 | 11.18M |
| June 30, 2016 | 4.060M |
| March 31, 2016 | 18.35M |
| December 31, 2015 | 34.01M |
| September 30, 2015 | 48.89M |
| June 30, 2015 | 64.42M |
| March 31, 2015 | 66.80M |
| December 31, 2014 | 68.20M |
| September 30, 2014 | 72.53M |
| June 30, 2014 | 73.95M |
| March 31, 2014 | 73.06M |
| December 31, 2013 | 71.86M |
| September 30, 2013 | 66.23M |
| June 30, 2013 | 60.35M |
| March 31, 2013 | 53.73M |
| December 31, 2012 | 49.41M |
| September 30, 2012 | 45.92M |
| June 30, 2012 | 44.93M |
| March 31, 2012 | 44.09M |
| December 31, 2011 | 41.46M |
| September 30, 2011 | 39.95M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
43.05M
Minimum
Jun 2019
272.45M
Maximum
Sep 2023
184.71M
Average
205.16M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 9.851B |
| Viking Therapeutics Inc | 76.90M |
| Akero Therapeutics Inc | 141.80M |
| 89bio Inc | 122.23M |
| Geron Corp | 125.05M |